Modification of hypoxic pulmonary vasoconstriction by aerosolized cromolyn sodium

T. Ahmed, W. Oliver, B. Marchette

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have previously demonstrated the role of mast cell degranulation in the mediation of hypoxic pulmonary vasoconstriction, and its prevention by intravenous cromolyn sodium. In the present investigation, we studied the modification of the hypoxic pulmonary vascular response by aerosolized cromolyn sodium. In seven conscious sheep on two separate days, pulmonary arterial pressure, pulmonary arterial wedge pressure and cardiac output were measured for the calculation of pulmonary vascular resistance (Rpv) along with arterial oxygen tension (PaO2) during room air breathing and breathing a hypoxic gas mixture (13% O2-87% N2), without and with cromolyn sodium administration. Cromolyn sodium (20 mg·kg-1) was administered as an aerosol before and during 13% O2 breathing. The sheep had comparable degrees of hypoxia during low oxygen breathing on both days (mean PaO2: 43 and 46 mmHg). Breathing hypoxic gas mixture caused pulmonary vasoconstriction, with increases in mean Rpv of 89% (p < 0.05). Aerosolized cromolyn sodium blunted the hypoxic pulmonary vascular response; mean Rpv increased by 27% (p < 0.05), which was significantly different from the increase during hypoxia without cromolyn sodium treatment (p < 0.05). We conclude that aerosolized cromolyn sodium (a mast cell membrane stabilizing agent) modifies hypoxic pulmonary vasoconstriction; however, unlike the intravenous form, aerosolized cromolyn sodium (at the dosage used) offers a partial protection.

Original languageEnglish
Pages (from-to)61-64
Number of pages4
JournalClinical Respiratory Physiology
Volume22
Issue number1
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Cromolyn Sodium
Vasoconstriction
Lung
Respiration
Arterial Pressure
Mast Cells
Blood Vessels
Sheep
Oxygen
Cell Degranulation
Pulmonary Wedge Pressure
Excipients
Aerosols
Cardiac Output
Vascular Resistance
Air
Cell Membrane

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Modification of hypoxic pulmonary vasoconstriction by aerosolized cromolyn sodium. / Ahmed, T.; Oliver, W.; Marchette, B.

In: Clinical Respiratory Physiology, Vol. 22, No. 1, 01.01.1986, p. 61-64.

Research output: Contribution to journalArticle

Ahmed, T. ; Oliver, W. ; Marchette, B. / Modification of hypoxic pulmonary vasoconstriction by aerosolized cromolyn sodium. In: Clinical Respiratory Physiology. 1986 ; Vol. 22, No. 1. pp. 61-64.
@article{4875afdd3cc64769903d7542ef0b4e5e,
title = "Modification of hypoxic pulmonary vasoconstriction by aerosolized cromolyn sodium",
abstract = "We have previously demonstrated the role of mast cell degranulation in the mediation of hypoxic pulmonary vasoconstriction, and its prevention by intravenous cromolyn sodium. In the present investigation, we studied the modification of the hypoxic pulmonary vascular response by aerosolized cromolyn sodium. In seven conscious sheep on two separate days, pulmonary arterial pressure, pulmonary arterial wedge pressure and cardiac output were measured for the calculation of pulmonary vascular resistance (Rpv) along with arterial oxygen tension (PaO2) during room air breathing and breathing a hypoxic gas mixture (13{\%} O2-87{\%} N2), without and with cromolyn sodium administration. Cromolyn sodium (20 mg·kg-1) was administered as an aerosol before and during 13{\%} O2 breathing. The sheep had comparable degrees of hypoxia during low oxygen breathing on both days (mean PaO2: 43 and 46 mmHg). Breathing hypoxic gas mixture caused pulmonary vasoconstriction, with increases in mean Rpv of 89{\%} (p < 0.05). Aerosolized cromolyn sodium blunted the hypoxic pulmonary vascular response; mean Rpv increased by 27{\%} (p < 0.05), which was significantly different from the increase during hypoxia without cromolyn sodium treatment (p < 0.05). We conclude that aerosolized cromolyn sodium (a mast cell membrane stabilizing agent) modifies hypoxic pulmonary vasoconstriction; however, unlike the intravenous form, aerosolized cromolyn sodium (at the dosage used) offers a partial protection.",
author = "T. Ahmed and W. Oliver and B. Marchette",
year = "1986",
month = "1",
day = "1",
language = "English",
volume = "22",
pages = "61--64",
journal = "Clinical Respiratory Physiology",
issn = "0272-7587",
publisher = "Pergamon Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Modification of hypoxic pulmonary vasoconstriction by aerosolized cromolyn sodium

AU - Ahmed, T.

AU - Oliver, W.

AU - Marchette, B.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - We have previously demonstrated the role of mast cell degranulation in the mediation of hypoxic pulmonary vasoconstriction, and its prevention by intravenous cromolyn sodium. In the present investigation, we studied the modification of the hypoxic pulmonary vascular response by aerosolized cromolyn sodium. In seven conscious sheep on two separate days, pulmonary arterial pressure, pulmonary arterial wedge pressure and cardiac output were measured for the calculation of pulmonary vascular resistance (Rpv) along with arterial oxygen tension (PaO2) during room air breathing and breathing a hypoxic gas mixture (13% O2-87% N2), without and with cromolyn sodium administration. Cromolyn sodium (20 mg·kg-1) was administered as an aerosol before and during 13% O2 breathing. The sheep had comparable degrees of hypoxia during low oxygen breathing on both days (mean PaO2: 43 and 46 mmHg). Breathing hypoxic gas mixture caused pulmonary vasoconstriction, with increases in mean Rpv of 89% (p < 0.05). Aerosolized cromolyn sodium blunted the hypoxic pulmonary vascular response; mean Rpv increased by 27% (p < 0.05), which was significantly different from the increase during hypoxia without cromolyn sodium treatment (p < 0.05). We conclude that aerosolized cromolyn sodium (a mast cell membrane stabilizing agent) modifies hypoxic pulmonary vasoconstriction; however, unlike the intravenous form, aerosolized cromolyn sodium (at the dosage used) offers a partial protection.

AB - We have previously demonstrated the role of mast cell degranulation in the mediation of hypoxic pulmonary vasoconstriction, and its prevention by intravenous cromolyn sodium. In the present investigation, we studied the modification of the hypoxic pulmonary vascular response by aerosolized cromolyn sodium. In seven conscious sheep on two separate days, pulmonary arterial pressure, pulmonary arterial wedge pressure and cardiac output were measured for the calculation of pulmonary vascular resistance (Rpv) along with arterial oxygen tension (PaO2) during room air breathing and breathing a hypoxic gas mixture (13% O2-87% N2), without and with cromolyn sodium administration. Cromolyn sodium (20 mg·kg-1) was administered as an aerosol before and during 13% O2 breathing. The sheep had comparable degrees of hypoxia during low oxygen breathing on both days (mean PaO2: 43 and 46 mmHg). Breathing hypoxic gas mixture caused pulmonary vasoconstriction, with increases in mean Rpv of 89% (p < 0.05). Aerosolized cromolyn sodium blunted the hypoxic pulmonary vascular response; mean Rpv increased by 27% (p < 0.05), which was significantly different from the increase during hypoxia without cromolyn sodium treatment (p < 0.05). We conclude that aerosolized cromolyn sodium (a mast cell membrane stabilizing agent) modifies hypoxic pulmonary vasoconstriction; however, unlike the intravenous form, aerosolized cromolyn sodium (at the dosage used) offers a partial protection.

UR - http://www.scopus.com/inward/record.url?scp=0022654070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022654070&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 61

EP - 64

JO - Clinical Respiratory Physiology

JF - Clinical Respiratory Physiology

SN - 0272-7587

IS - 1

ER -